Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial

04/08/2021 | 05:16am EDT

By Matt Grossman

Merck & Co. Inc.'s Keytruda drug met the primary endpoint of a Phase 3 trial to evaluate its use in treating an additional form of cancer, the Kenilworth, N.J.-based pharmaceutical company said Thursday.

The trial evaluated Keytruda's use as an adjuvant treatment for people with renal cell carcinoma following a nephrectomy, or a nephrectomy and the resection of metastatic lesions. Nephrectomy is the removal of a kidney. In the trial, which included 950 patients, subjects received either Keytruda or a placebo.

Keytruda led to a meaningful improvement in disease-free survival compared with the placebo in the trial, Merck said. Researchers will continue to evaluate overall survival among the patients in the trial.

Dr. Roy Baynes, Merck Research Laboratories' chief medical officer, said the company would share detailed results from the trial with regulators as soon as possible.

Keytruda, or pembrolizumab, has already been approved in the U.S. for roles in treating other forms of cancer.

Write to Matt Grossman at matt.grossman@wsj.com

(END) Dow Jones Newswires

04-08-21 0716ET

All news about MERCK & CO., INC.
04/11Corporate leaders plan new push on U.S. voting rights, will reconsider campai..
04/09With Georgia Voting Law, the Business of Business Becomes Politics
04/09MERCK  : KEYTRUDA (pembrolizumab) Demonstrated Superior Disease-Free Survival (D..
04/08MERCK  : Organon Announces Pricing of Senior Notes Offering
04/08Biggest Gains in Innovation in the Management Top 250 -- Journal Report
04/08MERCK  : Keytruda Trial Meets Primary Endpoint of Disease-Free Survival in Kidne..
04/08MERCK  : KEYTRUDA® (pembrolizumab) Demonstrated Superior Disease-Free Survival (..
04/08Merck's Cancer Drug Keytruda Meets Primary Endpoint in Phase 3 Trial
04/07ALKERMES  : Merck & Co. Enter Agreement to Test Cancer Duo Therapy
04/07Alkermes in Trial, Supply Agreement With Merck for Ovarian Cancer Treatment
More news
Financials (USD)
Sales 2021 52 159 M - -
Net income 2021 14 940 M - -
Net Debt 2021 16 243 M - -
P/E ratio 2021 13,4x
Yield 2021 3,42%
Capitalization 193 B 193 B -
EV / Sales 2021 4,01x
EV / Sales 2022 3,73x
Nbr of Employees 73 500
Free-Float 70,7%
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 23
Average target price 96,24 $
Last Close Price 76,31 $
Spread / Highest target 40,2%
Spread / Average Target 26,1%
Spread / Lowest Target 3,53%
EPS Revisions
Managers and Directors
Kenneth C. Frazier Chairman & Chief Executive Officer
Robert M. Davis President
Caroline A. Litchfield Chief Financial Officer & Executive Vice President
Sandy Tremps Vice President-R&D IT CIO
Dave Williams Chief Information & Digital Officer
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.-6.71%193 164
JOHNSON & JOHNSON2.46%424 524
ROCHE HOLDING AG0.21%288 043
PFIZER, INC.-0.57%204 161
NOVARTIS AG-3.29%197 172
ABBVIE INC.0.36%189 789